sy-5007
Medullary Thyroid Cancer
Shouyao Holdings (Beijing) Co. LTDPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Medullary Thyroid Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
Tarlatamab University of Arizona | Phase 2 | B |
Selpercatinib Eli Lilly and Company | Phase 2 | B |
Oxodotreotide M.D. Anderson Cancer Center | Phase 2 | CCC |
Everolimus National Cancer Institute (NCI) | Phase 1 | CCC |
View all 36 →
Same molecule, other indications
sy-5007 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →